Investor Relations

A leadership story in the field of advanced cell therapy

Investor Relations

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Vericel to Present at the 21st Annual Needham Growth Conference
CAMBRIDGE, Mass., Jan. 11, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest company overview at the 21 st Annual
View HTML
Toggle Summary Vericel Reports Publication of Outcomes Data From 954 Burn Patients Treated With Epicel in the Journal of Burn Care and Research
Results Demonstrate an Increased Survival Rate for Patients Treated with Epicel CAMBRIDGE, Mass., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of
View HTML
Toggle Summary Vericel Reports Record Third Quarter Revenues of $22.5 Million and Raises Full Year 2018 Revenue Guidance
58% Revenue Growth Over Third Quarter 2017 Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results
View HTML
Toggle Summary Vericel to Present at the Canaccord Genuity Medical Technologies & Diagnostic Forum
CAMBRIDGE, Mass. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the Canaccord
View HTML
Toggle Summary Vericel to Report Third-Quarter 2018 Financial Results on November 6, 2018
CAMBRIDGE, Mass. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2018 financial results and
View HTML
Toggle Summary Vericel to Present at Multiple Upcoming Conferences
CAMBRIDGE, Mass., Sept. 21, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, will be presenting at the following investor and industry conferences: Nick Colangelo, president and CEO, will present at
View HTML
Toggle Summary Vericel Announces Appointment of Jonathan Hopper as Chief Medical Officer
CAMBRIDGE, Mass. , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the appointment of Jonathan Hopper as Chief Medical Officer. Dr.
View HTML
Toggle Summary Vericel Reports Record Second Quarter Revenues of $19.0 Million and Raises Full Year 2018 Revenue Guidance
Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass. , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the second
View HTML
Toggle Summary Vericel to Present at the 38th Annual Canaccord Genuity Growth Conference
CAMBRIDGE, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo , president and CEO, will present the latest company overview at the 38th Annual
View HTML
Toggle Summary Vericel to Report Second-Quarter 2018 Financial Results on August 6, 2018
CAMBRIDGE, Mass. , July 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its second-quarter 2018 financial results and
View HTML

Day High:
Day Low:
Volume:
on
Copyright West LLC. Minimum 15 minutes delayed.